---
layout: default
title: Azilsartan Medoxomil
parent: 僅模型預測 (L5)
nav_order: 45
evidence_level: L5
indication_count: 0
---

# Azilsartan Medoxomil
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Azilsartan Medoxomil: Repurposing Evaluation — Insufficient Data to Proceed

## One-Sentence Summary

Azilsartan medoxomil (DrugBank: DB08822) is a drug candidate currently under assessment for repurposing potential.
The Evidence Pack contains **no TxGNN predictions** and two unresolved critical data gaps — mechanism of action and safety warnings — making a complete evaluation impossible at this stage.
**This evaluation is placed on Hold pending data remediation.**

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in current data |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | — |
| Evidence Level | — |
| Finland Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why No Evaluation Can Be Conducted

No mechanism of action data is available in the current Evidence Pack — this has been flagged as a **High-severity data gap (DG002)**. Without MOA data, a mechanistic rationale linking azilsartan medoxomil to any candidate indication cannot be established.

Furthermore, the TxGNN prediction pipeline has not generated any repurposing candidates for this drug (`predicted_indications` is empty). Without at least one predicted indication, the core analytical framework of this report — mechanistic plausibility, clinical trial evidence, literature support — has no target to evaluate.

No original indication data is present in the Evidence Pack either, preventing any baseline therapeutic comparison. Two data gaps currently block progress:

| Gap ID | Item | Severity | Impact |
|--------|------|----------|--------|
| DG001 | Package insert warnings & contraindications | **Blocking** | Cannot enter S1 safety screening |
| DG002 | Mechanism of action (MOA) | **High** | Cannot perform mechanistic relevance analysis |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No TxGNN repurposing predictions have been generated for this candidate, and two critical data gaps — safety warnings/contraindications (Blocking severity) and mechanism of action (High severity) — remain unresolved. A meaningful drug repurposing evaluation cannot be produced from this Evidence Pack in its current state.

**To proceed, the following is needed:**
- **[Blocking — DG001]** Download and parse the package insert PDF from the TFDA website to extract key warnings and contraindications
- **[High — DG002]** Query DrugBank API to retrieve mechanism of action data for DB08822
- **[Required]** Re-run the TxGNN prediction pipeline for DB08822 to generate repurposing candidates
- **[Required]** Regenerate the full Evidence Pack (targeting v5) once all inputs are available, then resubmit for evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

